Morgan Stanley Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Key Points

• Morgan Stanley raised its price target on Gilead to $175 (from $171) and kept an "overweight" rating, implying a potential upside of 35.8%.
• Near-term catalysts include the FDA granting priority review for bictegravir/lenacapavir with an August PDUFA date and Gilead's completion of the ~$7.8 billion Arcellx acquisition, which could lift HIV and oncology revenue but adds cash/outflow and integration risk.
• Gilead trades around $128.87 vs. a consensus target of $157.35 and FY2026 guidance of $8.45–$8.85 EPS (street ~8.62); insiders sold ~168,640 shares recently while institutions own ~83.7% of the stock.

Gilead Sciences (NASDAQ:GILD - Get Free Report) had its price target hoisted by stock analysts at Morgan Stanley from $171.00 to $175.00 in a research report issued to clients and investors on Tuesday,MarketScreener reports. The brokerage presently has an "overweight" rating on the biopharmaceutical company's stock. Morgan Stanley's price objective would indicate a potential upside of 35.80% from the company's previous close.

GILD has been the subject of several other reports. Barclays assumed coverage on shares of Gilead Sciences in a report on Friday, February 20th. They set an "equal weight" rating and a $155.00 price objective for the company. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an "overweight" rating in a report on Wednesday, February 11th. Weiss Ratings reissued a "buy (b)" rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Cantor Fitzgerald decreased their price objective on shares of Gilead Sciences from $155.00 to $115.00 and set an "overweight" rating for the company in a report on Friday, April 10th. Finally, BMO Capital Markets raised their price objective on shares of Gilead Sciences from $135.00 to $150.00 and gave the stock an "outperform" rating in a report on Monday, January 26th. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $157.35.

Gilead Sciences Stock Down 0.3%

Gilead Sciences stock traded down $0.39 during midday trading on Tuesday, hitting $128.87. 182,906 shares of the stock were exchanged, compared to its average volume of 6,740,588. Gilead Sciences has a 1 year low of $95.29 and a 1 year high of $157.29. The firm has a market cap of $159.95 billion, a P/E ratio of 19.02, a P/E/G ratio of 1.69 and a beta of 0.39. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The company has a 50 day moving average price of $141.38 and a two-hundred day moving average price of $132.39.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period last year, the business earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, sell-side analysts predict that Gilead Sciences will post 8.62 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Daniel Patrick O'day sold 115,640 shares of Gilead Sciences stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the transaction, the chief executive officer directly owned 613,912 shares of the company's stock, valued at approximately $92,086,800. The trade was a 15.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the transaction, the chief financial officer directly owned 176,191 shares of the company's stock, valued at $24,835,883.36. This trade represents a 1.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 168,640 shares of company stock valued at $25,292,650. Company insiders own 0.30% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Brighton Jones LLC lifted its position in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new stake in Gilead Sciences in the 4th quarter valued at about $215,000. Sivia Capital Partners LLC lifted its position in Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company's stock valued at $464,000 after purchasing an additional 602 shares during the last quarter. Ieq Capital LLC lifted its position in Gilead Sciences by 12.0% in the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company's stock valued at $13,160,000 after purchasing an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC lifted its position in Gilead Sciences by 18.6% in the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company's stock valued at $516,000 after purchasing an additional 674 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: FDA grants priority review for bictegravir 75 mg / lenacapavir 50 mg (BIC/LEN), a once‑daily single‑tablet HIV regimen for virologically suppressed adults — priority review accelerates the regulatory timeline and raises the chance of a faster commercial launch if approved; management now has an FDA PDUFA action date in August, which creates a clear near‑term catalyst for potential revenue upside. U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
• Positive Sentiment: Gilead completed the acquisition of Arcellx for ~$7.8B (cash $115/sh + a $5 CVR), adding Anito‑cel and strengthening Gilead’s cell‑therapy/oncology franchise (adds capabilities to Kite). This is a strategic growth move that expands potential commercial launch opportunities, though it also increases near‑term cash outflows and integration risk. Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
• Neutral Sentiment: Technical commentary notes GILD is retesting a long‑term cup‑base breakout and suggests additional upside if momentum holds — this is a market/technicals‑driven bullish signal but not a fundamental change to revenue or pipeline. Investors who trade on chart patterns may be supporting today’s buying. Gilead Sciences Crosses Critical Breakout Level. The Stock Can Gain 35% From Here.
• Negative Sentiment: A shareholder resolution from AIDS Healthcare Foundation requests greater transparency on Gilead’s patent exclusivities — this could raise governance scrutiny and potentially pressure management disclosure around patent cliffs and revenue protection for key drugs. While not an immediate cash impact, it is a possible headwind for investor sentiment. AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.